Clinically important, the data provided suggest that NDRG1 may offer a powerful diagnostic tool for the grading of pancreatic cancers, whereas better characterising of the protein may help to decide on how aggressive the adjuvant therapy should be planned. This evidence concerns the gene NDRG1 and pancreatic neoplasm.